Evidence map›Paper›PMID 37941034›Full record

ArticleMolecular cytogenetics2023

Cytogenomic features of Richter transformation.

Renata Woroniecka, Grzegorz Rymkiewicz, Zbigniew Bystydzienski, Barbara Pienkowska-Grela, Jolanta Rygier, Natalia Malawska, Katarzyna Wojtkowska, Nikolina Goral, Katarzyna Blachnio, Marcin Chmielewski and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cytogenetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. microRNA Profile of High-Grade B-Cell Lymphoma with 11q Aberration.International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Renata WoronieckaCytogenetic Laboratory, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgen Street, Warsaw, Poland. renata.woroniecka@nio.gov.pl.
Grzegorz RymkiewiczFlow Cytometry Laboratory, Department of Cancer Pathomorphology, Maria Sklodowska - Curie National Research Institute of Oncology, Warsaw, Poland.
Zbigniew BystydzienskiFlow Cytometry Laboratory, Department of Cancer Pathomorphology, Maria Sklodowska - Curie National Research Institute of Oncology, Warsaw, Poland.
Barbara Pienkowska-GrelaCytogenetic Laboratory, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgen Street, Warsaw, Poland.
Jolanta RygierCytogenetic Laboratory, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgen Street, Warsaw, Poland.
Natalia MalawskaCytogenetic Laboratory, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgen Street, Warsaw, Poland.
Katarzyna WojtkowskaCytogenetic Laboratory, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgen Street, Warsaw, Poland.
Nikolina GoralCytogenetic Laboratory, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgen Street, Warsaw, Poland.
Katarzyna BlachnioFlow Cytometry Laboratory, Department of Cancer Pathomorphology, Maria Sklodowska - Curie National Research Institute of Oncology, Warsaw, Poland.
Marcin ChmielewskiFlow Cytometry Laboratory, Department of Cancer Pathomorphology, Maria Sklodowska - Curie National Research Institute of Oncology, Warsaw, Poland.
Magdalena Bartnik-GlaskaDepartment of Medical Genetics, Institute of Mother and Child, 01-211, Warsaw, Poland.
Beata GrygalewiczCytogenetic Laboratory, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgen Street, Warsaw, Poland.
The Maria Sklodowska-Curie National Research Institute of Oncology · PL

Funding

Count Jakub Potocki's Foundation 299/21
6 · The paper itself

Abstract

backgroundRichter transformation (RT) is the development of aggressive lymphoma in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This rare disease is characterised by dismal prognosis. In recent years, there has been a deeper understanding of RT molecular pathogenesis, and disruptions of apoptosis (TP53) and proliferation (CDKN2A, MYC, NOTCH1) has been described as typical aberrations in RT.

resultsA single-institution cohort of 33 RT patients were investigated by karyotyping, fluorescence in situ hybridization and single nucleotide polymorphism/copy number (CN) arrays. Most of RTs were typically manifested by diffuse large B-cell lymphoma, not otherwise specified, among the remaining cases one was classified as high-grade B-cell lymphoma with 11q aberrations. The most frequent alterations (40-60% of cases) were represented by MYC rearrangement/gain, deletions of TP53 and CDKN2A, IGH rearrangement and 13q14 deletion. Several other frequent lesions included losses of 14q24.1-q32.33, 7q31.33-q36.3, and gain of 5q35.2. Analysis of 13 CLL/SLL-RT pairs showed that RT arised from the CLL/SLL by acquiring of 10 ~ 12 cytogenetic or CN lesions/case, but without acquisition of loss of heterozygosity regions. Our result affirmed the higher genetic complexity in RT than CLL/SLL and confirmed the linear features of RT clonal evolution as predominant.

conclusionsCytogenomic profile was concordant with the literature data, however the role of IGH rearrangement, 14q deletion and 5q35.2 gain need to be explored. We anticipate that further characterization of RT lesions will probably facilitate better understanding of the RT clonal evolution.

Indexed as

11q gain/loss13q14 deletionCDKN2AChronic lymphocytic leukemiaHigh-grade B-cell lymphoma with 11q aberrationsIGH deletionIGH rearrangementMYCRichter transformationSmall lymphocytic lymphomaTP53

Identifiers

PMID37941034
PMCPMC10631075
OpenAlexW4388493667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.